Findings

What do systematic reviews say?

1,078 questions · 1,098 findings · 33 reviews · Skin

Sort:Best matchNewest Highest certainty Download CSV

No studies found 396 · 36.1%GRADE not reported 89 · 8.1%Very low 181 · 16.5%Low 183 · 16.7%Moderate 196 · 17.9%High 53 · 4.8%

Azelaic acid vs placebo

Duration of remission ‐ not measured · Participants with rosacea

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for rosacea 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Topical ivermectin vs placebo

HRQOL DLQI and RosaQoL · Participants with rosacea

1 finding from 1 review

Interventions for rosacea 2015 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 1371 participants
High

Topical ivermectin vs placebo

Participant‐assessed improvement in rosacea severity · Participants with rosacea

1 finding from 1 review

Interventions for rosacea 2015 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 1371 participants
High

Topical ivermectin vs placebo

Proportion of participants with adverse event · Participants with rosacea

1 finding from 1 review

Interventions for rosacea 2015 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 1371 participants
High

Metronidazole vs placebo

Participant‐assessed improvement in rosacea severity · Participants with rosacea

1 finding from 1 review

Interventions for rosacea 2015 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 252 participants
Moderate

Topical ivermectin vs placebo

Physician‐assessed improvement in rosacea severity · Participants with rosacea

1 finding from 1 review

Interventions for rosacea 2015 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 1371 participants
High

Topical ivermectin vs placebo

Assessment of erythema or telangiectasia ‐ not measured · Participants with rosacea

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for rosacea 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Topical ivermectin vs placebo

Lesion count · Participants with rosacea

1 finding from 1 review

Interventions for rosacea 2015 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 1371 participants
High

Topical ivermectin vs placebo

Time needed until improvement of the skin lesions · Participants with rosacea

1 finding from 1 review

Interventions for rosacea 2015 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 1371 participants
High

Topical ivermectin vs placebo

Duration of remission ‐ not measured · Participants with rosacea

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for rosacea 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Topical brimonidine vs vehicle

HRQOL ‐ not measured · Participants with rosacea

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for rosacea 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Topical brimonidine vs vehicle

Participant‐assessed improvement in rosacea severity Patient Satisfaction Assessment ‐ grade 2 improvement · Participants with rosacea

1 finding from 1 review

Interventions for rosacea 2015 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 553 participants
High

Topical brimonidine vs vehicle

Proportion of participants with adverse event · Participants with rosacea

1 finding from 1 review

Interventions for rosacea 2015 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 553 participants
High

Topical brimonidine vs vehicle

Physician‐assessed improvement in rosacea severity ‐ not measured · Participants with rosacea

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for rosacea 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Topical brimonidine vs vehicle

Assessment of erythema or telangiectasia · Participants with rosacea

1 finding from 1 review

Interventions for rosacea 2015 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 553 participants
High

Metronidazole vs placebo

Proportion of participants with adverse event · Participants with rosacea

Metronidazole showed no clear difference in proportion of participants with adverse event compared with placebo (high certainty).

1 finding from 1 review

Interventions for rosacea 2015 · Cochrane Headline outcomes only
RR 1.19 [0.94, 1.51]
6 studies · 1773 participants
High

Topical brimonidine vs vehicle

Lesion count ‐ not measured · Participants with rosacea

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for rosacea 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Topical brimonidine vs vehicle

Time needed until improvement of the skin lesions · Participants with rosacea

1 finding from 1 review

Interventions for rosacea 2015 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 553 participants
High

Topical brimonidine vs vehicle

Duration of remission ‐ not measured · Participants with rosacea

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for rosacea 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Azelaic acid vs topical metronidazole

HRQOL ‐ not measured · Participants with rosacea

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for rosacea 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found